Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 3

1(16.7%)

Phase 2

1(16.7%)

6Total

N/A(4)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02803489Not ApplicableTerminated

Evaluation of the Performance of an e-Health System

Role: collaborator

NCT07153237Not ApplicableNot Yet Recruiting

Clinical Performance and Safety of STYLAGE® HydroMax

Role: collaborator

NCT06779981Completed

A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness

Role: collaborator

NCT06582277Phase 2Completed

Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836

Role: collaborator

NCT05146310Not ApplicableCompleted

Prospective, Multicenter, Non-comparative Clinical Investigation to Support Safety & Effectiveness of I.SPACE®

Role: collaborator

NCT04813614Not ApplicableCompleted

Effectiveness and Safety of STYLAGE® M Lidocaïne for Lips' Volume Augmentation and/or Redefinition of the Outline of the Lips (SMILE)

Role: collaborator

NCT01120405Phase 3Completed

Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery

Role: collaborator

All 7 trials loaded